Related Experiment Videos
[Studies on meropenem in the field of pediatrics]
Insights
Meropenem (MEPM) demonstrated high clinical effectiveness and excellent safety in pediatric patients, achieving a 90% efficacy rate and 100% pathogen eradication. Cerebrospinal fluid penetration was also noted in meningitis cases.
Area of Science:
- Pediatric infectious diseases
- Pharmacokinetics and pharmacodynamics
- Antibiotic therapy
Background:
- Meropenem (MEPM) is a broad-spectrum carbapenem antibiotic.
- Pediatric infections require specific pharmacokinetic and efficacy data.
- Limited data exists on meropenem's use in pediatric populations.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical effectiveness of meropenem in pediatric patients.
- To assess meropenem's efficacy against various bacterial infections in children.
- To determine the safety profile of meropenem in pediatric use.
Main Methods:
- Case study of a pediatric patient with suppurative meningitis treated with meropenem.
- Clinical trial involving 10 pediatric patients with diverse bacterial infections.
- Administration of meropenem via intravenous drip infusion.
- Monitoring of drug concentration in cerebrospinal fluid and blood.
- Evaluation of clinical response and pathogen eradication.
Main Results:
- In a meningitis case, meropenem concentration in cerebrospinal fluid was 3.6% of blood concentration.
- Overall clinical efficacy rate was 90% (7 very good, 2 good, 1 fair).
- Pathogen eradication rate was 100% for all 6 isolated strains (Staphylococcus aureus, Klebsiella pneumoniae, Haemophilus influenzae).
Conclusions:
- Meropenem is clinically effective and well-tolerated in pediatric patients.
- The drug shows significant efficacy in treating serious pediatric infections.
- Meropenem is a safe treatment option for children, with no observed side effects or significant laboratory abnormalities.
Abstract:
The pharmacokinetics and the clinical effectiveness of meropenem (MEPM) were examined in the field of pediatrics. The results are summarized as follows. 1. A 4-year-6-month-old girl with suppurative meningitis (Haemophilus influenzae) was treated by intravenous drip infusion of MEPM in a daily dose of 29 mg/kg which was divided into 4 dosages, each dosage being infused over 30 minutes, and the drug concentration in cerebrospinal fluid was determined. Upon completion of infusion on the 2nd day of treatment, the drug concentration was 2.52 micrograms/ml, which corresponded to 3.6% of the drug concentration in the blood. 2. MEPM was used in 10 patients, including 3 with suppurative lymphnoditis, 2 with staphylococcal scalded skin syndrome (SSSS) and 1 each with pneumonia, suppurative meningitis, suppurative knee arthritis, facial phlegmon and pyelonephritis. The daily doses ranged from 30 to 117.6 mg/kg, divided into 3 to 4 dosages and administered via intravenous drip infusion over 30 minutes. Clinical responses were evaluated as very good in 7 patients, good in 2 patients and fair in 1 patient, with an efficacy rate of 90%. 3. Isolated pathogens were 2 strains of Staphylococcus aureus, 1 strain of Klebsiella pneumoniae and 3 strains of Haemopilus influenzae. All of the 6 strains were eradicated, with an eradication rate of 100%. 4. In the safety evaluation, none of the patients was observed to have any side effects. Furthermore, no abnormal variations were found in laboratory test data possibly attributable to administration of MEPM.